<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0FED1C47-231B-46E3-9C8D-2CE5528F10B1"><gtr:id>0FED1C47-231B-46E3-9C8D-2CE5528F10B1</gtr:id><gtr:name>The Karolinska Institute, Stockholm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F"><gtr:id>F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F</gtr:id><gtr:name>Celgene</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/38AAC27D-B957-44C3-A06A-8E19C2A33360"><gtr:id>38AAC27D-B957-44C3-A06A-8E19C2A33360</gtr:id><gtr:name>Forma Therapeutics</gtr:name><gtr:address><gtr:line1>NTU</gtr:line1><gtr:line2>SPMS-04-01</gtr:line2><gtr:line3>21 Nanyan Link</gtr:line3><gtr:postCode>637371</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0FED1C47-231B-46E3-9C8D-2CE5528F10B1"><gtr:id>0FED1C47-231B-46E3-9C8D-2CE5528F10B1</gtr:id><gtr:name>The Karolinska Institute, Stockholm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F"><gtr:id>F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F</gtr:id><gtr:name>Celgene</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/38AAC27D-B957-44C3-A06A-8E19C2A33360"><gtr:id>38AAC27D-B957-44C3-A06A-8E19C2A33360</gtr:id><gtr:name>Forma Therapeutics</gtr:name><gtr:address><gtr:line1>NTU</gtr:line1><gtr:line2>SPMS-04-01</gtr:line2><gtr:line3>21 Nanyan Link</gtr:line3><gtr:postCode>637371</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DE3AB9E4-468F-4A59-9D72-9C7ADF27B92F"><gtr:id>DE3AB9E4-468F-4A59-9D72-9C7ADF27B92F</gtr:id><gtr:firstName>Benedikt</gtr:firstName><gtr:otherNames>Mathias</gtr:otherNames><gtr:surname>Kessler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501068"><gtr:id>0C579A0E-7DE5-460C-BC5A-9E82F3779DF9</gtr:id><gtr:title>Novel proteases with deubiquitylation activity: examination of function in T lymphocytes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501068</gtr:grantReference><gtr:abstractText>Work over the last 25 years has established the importance of regulating protein ubiquitylation in a wide range of cellular functions including cell cycle control, transcriptional regulation, and cell signaling. These processes are disturbed in many human diseases such as cancer, neurodegeneration and immunological disorders. So far, most analyses have focused on mechanisms controlling ubiquitin ligation. However, the recognition of extensive classes of deubiquitylating enzymes (DUBs) strongly suggests a regulatory (as opposed to purely recycling) role for DUBs. Thus it is anticipated that the planned analysis of one class of these enzymes would shed light on important and medically relevant aspects of cellular physiology. A novel class of these enzymes containing an ovarian tumor domain (OTU), which encodes for a putative ubiquitin-specific cysteine protease, has been recently identified. This domain is conserved throughout evolution. Obubain 1 (OTUB1), a member of this protein family, does not contribute to the deubiquitylation of the bulk of cytosolic proteins. Preliminary evidence suggests that OTUB1 plays a specific role in the regulation of antigen responsiveness of T lymphocytes. Insights into this process could have important implications for our understanding of immune-modulation, and may identify OTU containing proteins as novel therapeutic targets.</gtr:abstractText><gtr:technicalSummary>Work over the last 25 years has established the importance of regulating protein ubiquitylation in a wide range of cellular functions including cell cycle control, transcriptional regulation, and diverse aspects of cell signaling. These processes are disturbed in many human diseases such as cancer, neurodegeneration and immunological disorders involving abnormal accumulations of proteins in cells. So far, most analyses have focused on mechanisms controlling ubiquitin ligation. However, the recognition of extensive classes of deubiquitylating enzymes (DUBs) strongly suggests a regulatory (as opposed to purely recycling) role for DUBs. Thus it is anticipated that the planned analysis of one class of these enzymes would shed light on important and medically relevant aspects of cellular physiology. A novel class of these enzymes containing an ovarian tumor domain (OTU), which encodes for a putative ubiquitin-specific cysteine protease, has been recently identified. This domain is conserved throughout evolution. Obubain 1 (OTU1), a member of this protein family, does not contribute to the deubiquitylation of the bulk of cytosolic proteins. Preliminary evidence suggests that OTU1 plays a specific role in the regulation of antigen responsiveness of T lymphocytes. Further evaluation of this phenomenon will not only shed light on the role of ubiquitin-linked mechanisms in signaling in general, but also on how these proteins may regulate the T cell signaling cascade in particular. Insights into this process could have important implications for our understanding of immune-modulation, and may identify OTU containing proteins as novel therapeutic targets.</gtr:technicalSummary><gtr:fund><gtr:end>2009-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>321624</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Neuroscience</gtr:department><gtr:description>The ubiquitin-proteasome system in aging</gtr:description><gtr:id>7CFC984F-65C4-411E-8579-55173AA3B8CC</gtr:id><gtr:impact>Swedish postdoctoral fellowship

Joint publications:
PMID: 20940294
PMID: 17503500</gtr:impact><gtr:partnerContribution>Swedish postdoctoral fellowship

joint publications:
PMID: 20940294
PMID: 17503500</gtr:partnerContribution><gtr:piContribution>Biochemical characterisation of proteasome complexes isolated from young and old rat muscle tissue, proteomics analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Epidemiology Unit</gtr:department><gtr:description>Ubiquitin processing enzymes in DNA repair</gtr:description><gtr:id>23279209-F313-449E-BCD5-A30F157A5ABD</gtr:id><gtr:impact>Publication 19713937</gtr:impact><gtr:partnerContribution>Scientific collaboration, biochemistry expertise, molecular biology</gtr:partnerContribution><gtr:piContribution>My group has contributed with biochemical experiments to isolate ubiquitin processing enzymes that contribute to control DNA repair mechanisms</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Celgene</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>DUB Alliance - CRT/Forma/Celgene</gtr:description><gtr:id>FECD4005-0773-49F5-BA3C-E6C848180D8B</gtr:id><gtr:impact>Novel DUB inhibitors (anti-cancer drug candidates)
Multidisciplinary approach between HTS, biochemistry, proteomics &amp;amp; cell biology</gtr:impact><gtr:partnerContribution>Development of small molecule DUB inhibitors, Ubiquitin research tools</gtr:partnerContribution><gtr:piContribution>Development of DUB inhibitors for cancer treatment
Alliance between my lab and Cancer Research Technologies (CRT), Forma Therapeutics and Celgene</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research Technology (CRT)</gtr:department><gtr:description>DUB Alliance - CRT/Forma/Celgene</gtr:description><gtr:id>872809C8-8F25-469E-80E4-9E0D8E33DD96</gtr:id><gtr:impact>Novel DUB inhibitors (anti-cancer drug candidates)
Multidisciplinary approach between HTS, biochemistry, proteomics &amp;amp; cell biology</gtr:impact><gtr:partnerContribution>Development of small molecule DUB inhibitors, Ubiquitin research tools</gtr:partnerContribution><gtr:piContribution>Development of DUB inhibitors for cancer treatment
Alliance between my lab and Cancer Research Technologies (CRT), Forma Therapeutics and Celgene</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust/Cancer Research UK Gurdon Institute</gtr:department><gtr:description>DUBs in DNA Repair</gtr:description><gtr:id>439BF2B1-FFFF-4B2F-82E0-6B4CE0691A58</gtr:id><gtr:impact>Interesting novel mechanisms of DUBs function in the context of DDR. This will provide novel entry points for new drug development to treat cancer.</gtr:impact><gtr:partnerContribution>DDR biochemistry and biology.</gtr:partnerContribution><gtr:piContribution>Application of mass spectrometry and proteomics to study DUBs involved in DNA double break strand repair mechanisms (DDR).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FORMA Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>DUB Alliance - CRT/Forma/Celgene</gtr:description><gtr:id>B4570D1A-5DA9-4B21-8D76-977EBD73B9B7</gtr:id><gtr:impact>Novel DUB inhibitors (anti-cancer drug candidates)
Multidisciplinary approach between HTS, biochemistry, proteomics &amp;amp; cell biology</gtr:impact><gtr:partnerContribution>Development of small molecule DUB inhibitors, Ubiquitin research tools</gtr:partnerContribution><gtr:piContribution>Development of DUB inhibitors for cancer treatment
Alliance between my lab and Cancer Research Technologies (CRT), Forma Therapeutics and Celgene</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Sciences Centre</gtr:department><gtr:description>Role of the ubiquitin proteasome system in regulation of transcription</gtr:description><gtr:id>5804B0FD-34CD-404F-928C-5C965509D984</gtr:id><gtr:impact>PMID: 20516216</gtr:impact><gtr:partnerContribution>Scientific collaboration on the role of the ubiquitin proteasome system in regulation of transcription

Publication
PMID: 20516216</gtr:partnerContribution><gtr:piContribution>Scientific collaboration using mass spectrometry and proteomics approaches to assess the role of the ubiquitin proteasome system in the regulation of transcription</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Cell biology of deubiquitinating enzymes</gtr:description><gtr:id>00B326E4-23DF-4FD0-9283-9F6C4DB46ED4</gtr:id><gtr:impact>Publication: 17927229 We also have a manuscript describing a role of the deubiquitinating enyzme CYLD in wnt signalling that is currently under review.</gtr:impact><gtr:partnerContribution>The collaboration with Dr. Madelon Maurice's group at the University of Utrecht (NL) is focussed on the cell biology of deubiquitinating enzymes (DUBs). We have previously described proteome changes upon the regulation of USP7/HAUSP expression, a DUB involved in cancer biology. Current experimental efforts are directed towards determining a role for the cylindromatosis suppressor gene CYLD and wnt signalling.</gtr:partnerContribution><gtr:piContribution>The role of my group is to perform the biochemical experiments that describe the enyzmatic properties of the DUBs under study. Furthermore, my group is performing the proteomics and mass spectrometry related work to study the specificity of ubiquitination, the type of ubiquitin chains and mapping the sites of ubiquitination of DUB substrates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Molecular mechanisms of oxygen sensing</gtr:description><gtr:id>8BA21C9A-B04B-4730-A0BD-D6C67139E146</gtr:id><gtr:impact>Financed two research positions (RA and bioinformatician)

Joint publications:
PMID: 18936059
PMID: 17573339
PMID: 17339318
PMID: 20583823
PMID: 19574390
PMID: 18972478</gtr:impact><gtr:partnerContribution>Financed two research positions (RA and bioinformatician)

Joint publications:
PMID: 18936059
PMID: 17573339
PMID: 17339318
PMID: 20583823
PMID: 19574390
PMID: 18972478</gtr:partnerContribution><gtr:piContribution>Proteomics and mass spectrometry based analysis of protein modifications controlled by oxygen sensing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Work experience for student</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6688D24F-A6B1-43C4-9CE1-D3017F818C9A</gtr:id><gtr:impact>Organized a day of work experience for sixth form student

Student decided to study medical sciences at the University of Cambridge...</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Publication for a wider audience not only restricted to academia</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>330EE382-B91B-4E30-A609-706E7FBBE706</gtr:id><gtr:impact>General description of novel technological advances in analysing biological samples

The journal in which this article was published is widely read amongst professional in the pharma industry Publication: The Column http://www.nxtbook.com/nxtbooks/advanstaruk/thecolumn1007/index.php</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Race for Life</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>56DC4DF6-980B-43D5-BA6C-623E0A8A126E</gtr:id><gtr:impact>Team building exercise
Websites:
http://www.ccmp.ox.ac.uk/public-engagement
http://www.raceforlifesponsorme.org/kessler-group/eurl.axd/289728e11b02e2478608452b80d5ec5e

Raising awareness for sport as a way to increase health</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science day Junior School</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>07489D83-9C6C-481D-832C-53F8D1E45E10</gtr:id><gtr:impact>A &amp;quot;Science Day&amp;quot; was organized by members of the Kessler group for the Haddenham Community Junior School, Buckinghamshire, year 5 pupils (25th March 2010).

Website:
http://www.ccmp.ox.ac.uk/public-engagement

Enthusiastic response from pupils and teachers proposed to repeat this event in the future.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Accelerator Award</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>65248B2E-0CC4-45C0-B7D1-213208F440AD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>T cell based vaccine for HIV</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>14B8888E-A74B-4C8A-AAEC-DAF5584A3D24</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>116018</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Substrate Peptidomimetic Inhibitors (SPIs) of the COP9 signalosome</gtr:description><gtr:end>2020-11-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/N034295/1</gtr:fundingRef><gtr:id>4BCD717F-6A3B-486D-A380-959642FEF96F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISSF Wellcome Trust</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>B01BDC48-26F6-4DE2-A6FA-A9FFA8405FE2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>FP 7 PROLIFICA</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:id>0978BECD-BE3E-4CEA-8A8C-E05FD08ACF2C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARC funding, Proteomic investigation in ankylosing spondylitis (co-PI with Dr. Paul Bowness, University of Oxford)</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>C2947B40-03EA-4AC5-80A1-5E9BB8FDC954</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208899</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Cancer Research Technology (CRT)</gtr:department><gtr:description>CRT/CRUK - DUB Alliance</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>C54D2808-B427-4338-A6BE-9303F0BB89DE</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The John Fell Fund</gtr:department><gtr:description>Oxford University John Fell Fund (Proteomics Bioinformatics)</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>515F8DA6-112B-42C0-88F9-1AA4097926BD</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Rapid, direct detection of deubiquinating enzymes in cell lysates and whole cells with high-throughput and multiplexing possibilities.

http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013144656&amp;amp;recNum=3&amp;amp;docAn=GB2013050848&amp;amp;queryString=PA/%22isis%20innovation%22%20&amp;amp;maxRec=821

Website:
http://www.isis-innovation.com/licensing/8918.html</gtr:description><gtr:id>96CBCC4A-F42A-4258-8808-726245833C3B</gtr:id><gtr:impact>These ubiquitin-based probes will find utility as research tools for cellular and molecular biology and proteomics and may be particularly useful for screening compounds in order to identify potential inhibitors of deubiquitinating enzymes as novel anti-cancer and anti-viral agents.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2013144656</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Flexible ubiquitin probes</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>DUB inhibitors for cancer research through the DUB Alliance (CRT-Cancer Research Technologies in collaboration with five academic labs, Forma Therapeutics and Celgene</gtr:description><gtr:id>A9ABBEC2-5E5B-4805-9B83-85C38FDC6843</gtr:id><gtr:impact>DUB inhibitors have not yet been used in man, but the DUB Alliance will be one of the first trying to conduct this for the development of novel anticancer therapeutics.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DUB inhibitors for cancer research through the DUB Alliance</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Flexible ubiquitin probes

Oxford inventors have designed ubiquitin- and ubiquitin-like active site probes which can be modified, using click-chemistry, to add functional groups such as fluorescent tags. These probes offer numerous advantages for profiling DUBs (deubiquitinating enzymes) in cell extracts, as well as intact cells.

This strategy has the advantage of requiring minimal protein modification, affording an easy and generally applicable synthesis route.

The click-chemistry feature also has the key advantage of enabling a variety of functional groups to be added, allowing further expansion and diversification of the ubiquitin-based probes.</gtr:description><gtr:id>F583D2A1-B747-4184-AA66-5405CC5B233A</gtr:id><gtr:impact>This resulted in a number of joint research publications, and is the basis for the collaboration with the DUB alliance (financed by pharma), with the aim to find DUB based inhibitors that can be developed into novel anti-cancer drugs.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Ubiquitin active site probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.isis-innovation.com/licensing/8918.html</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In order to provide a better way to analyse mass spectrometry (MS) data in our laboratory, we have developed a novel easy-to-use proteomics analysis pipeline that is accessible over the web.</gtr:description><gtr:id>71C210F7-F334-40DC-B164-A955D635C935</gtr:id><gtr:impact>Many research groups including our own are using this MS analysis pipeline to perform extensive data mining of large proteomic data sets. Many biological and biomedical research projects will highly benefit from this research tool in the future. A technology note describing this new tool is currently under review.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Proteomics MS data analysis pipeline</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have created a series of mammalian and bacterial expression plasmids for the deubiquitinating enyzmes OTUB1 and OTUB2</gtr:description><gtr:id>292BFCE4-759C-4217-95FB-262D3524E169</gtr:id><gtr:impact>Experimental results obtained with these expression plasmids were published in the following research article: 18954305 Since then, a number of other scientific groups have requested these reagents</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DUBs expression plasmids</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>UBIq</gtr:companyName><gtr:description>Development of tools to study the ubiquitin proteasome system</gtr:description><gtr:id>6D2B30E1-DD82-4785-9396-05688E36046B</gtr:id><gtr:impact>Novel reagents are being developed and offered to the research community, which long-term potential to be used for the discovery of clinical biomarkers.</gtr:impact><gtr:yearCompanyFormed>2009</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3A56AE2-4094-4A35-83FD-8E786BE4BC24"><gtr:id>D3A56AE2-4094-4A35-83FD-8E786BE4BC24</gtr:id><gtr:title>Ubiquitin ligase UBR3 regulates cellular levels of the essential DNA repair protein APE1 and is required for genome stability.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/02ef530f773422f7c06aeaee897e9cc2"><gtr:id>02ef530f773422f7c06aeaee897e9cc2</gtr:id><gtr:otherNames>Meisenberg C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31C582D0-FE50-40AD-A591-076EB01C759E"><gtr:id>31C582D0-FE50-40AD-A591-076EB01C759E</gtr:id><gtr:title>Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/170b0dfa23f35e1297d53e800812b20d"><gtr:id>170b0dfa23f35e1297d53e800812b20d</gtr:id><gtr:otherNames>Blackledge NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D1EB86A-EE3F-40C0-9475-30C527C9E99D"><gtr:id>7D1EB86A-EE3F-40C0-9475-30C527C9E99D</gtr:id><gtr:title>Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CBBF4630-EF9E-4A1A-B67F-F55F5B40E145"><gtr:id>CBBF4630-EF9E-4A1A-B67F-F55F5B40E145</gtr:id><gtr:title>Deubiquitinase Usp8 regulates a-synuclein clearance and modifies its toxicity in Lewy body disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/162419e29842279e59d36a09904fe1b5"><gtr:id>162419e29842279e59d36a09904fe1b5</gtr:id><gtr:otherNames>Alexopoulou Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87B89D78-4823-4D6B-AE56-CF63D7C046EE"><gtr:id>87B89D78-4823-4D6B-AE56-CF63D7C046EE</gtr:id><gtr:title>Post-translational modification of the deubiquitinating enzyme otubain 1 modulates active RhoA levels and susceptibility to Yersinia invasion.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7fa12e19b3a87c86e7b201ababa1a7c"><gtr:id>a7fa12e19b3a87c86e7b201ababa1a7c</gtr:id><gtr:otherNames>Edelmann MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B27FFF7-ECEA-4ED6-9C1F-3CB475F4B540"><gtr:id>3B27FFF7-ECEA-4ED6-9C1F-3CB475F4B540</gtr:id><gtr:title>The human otubain2-ubiquitin structure provides insights into the cleavage specificity of poly-ubiquitin-linkages.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80b385801defdd9ce2b3d02c9f8ab4dd"><gtr:id>80b385801defdd9ce2b3d02c9f8ab4dd</gtr:id><gtr:otherNames>Altun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1057E2C-789E-422D-A9F3-03668A56864C"><gtr:id>B1057E2C-789E-422D-A9F3-03668A56864C</gtr:id><gtr:title>Phosphorylation of PNKP by ATM prevents its proteasomal degradation and enhances resistance to oxidative stress.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/49476d1b28bfaa1e8c55484389b0138d"><gtr:id>49476d1b28bfaa1e8c55484389b0138d</gtr:id><gtr:otherNames>Parsons JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8FE2C0B5-B23D-48D4-B406-DF2E5DDE745A"><gtr:id>8FE2C0B5-B23D-48D4-B406-DF2E5DDE745A</gtr:id><gtr:title>E3 ligases determine ubiquitination site and conjugate type by enforcing specificity on E2 enzymes.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ff7140e52434a960b29be62561534e8"><gtr:id>5ff7140e52434a960b29be62561534e8</gtr:id><gtr:otherNames>David Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5BC4EA6-803C-4E25-838B-F91F31D8A51C"><gtr:id>C5BC4EA6-803C-4E25-838B-F91F31D8A51C</gtr:id><gtr:title>Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2dd798d753b6242950f4fe4166551ba7"><gtr:id>2dd798d753b6242950f4fe4166551ba7</gtr:id><gtr:otherNames>Hipp MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BCB6A95A-878A-473D-8A59-43F13EFD67D6"><gtr:id>BCB6A95A-878A-473D-8A59-43F13EFD67D6</gtr:id><gtr:title>Biochemical and Mass Spectrometry-Based Approaches to Profile SUMOylation in Human Cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db23066eb1e6d0badd53a2e7fc531e8"><gtr:id>6db23066eb1e6d0badd53a2e7fc531e8</gtr:id><gtr:otherNames>Kessler BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2FE8B0A6-98FF-45A5-AE4E-358C719F5E36"><gtr:id>2FE8B0A6-98FF-45A5-AE4E-358C719F5E36</gtr:id><gtr:title>USP4 Auto-Deubiquitylation Promotes Homologous Recombination.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff18818136caa2338947cf4530a4c265"><gtr:id>ff18818136caa2338947cf4530a4c265</gtr:id><gtr:otherNames>Wijnhoven P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B637927C-0286-446D-AA1F-D1FD950D8F64"><gtr:id>B637927C-0286-446D-AA1F-D1FD950D8F64</gtr:id><gtr:title>Profiling ubiquitin linkage specificities of deubiquitinating enzymes with branched ubiquitin isopeptide probes.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fd49352d50c4f1fbb21013cd4c3e0918"><gtr:id>fd49352d50c4f1fbb21013cd4c3e0918</gtr:id><gtr:otherNames>Iph?fer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0B611DE-0BF3-4999-9D8B-C8E2A0A7EF9F"><gtr:id>A0B611DE-0BF3-4999-9D8B-C8E2A0A7EF9F</gtr:id><gtr:title>Ubiquitin - omics reveals novel networks and associations with human disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db23066eb1e6d0badd53a2e7fc531e8"><gtr:id>6db23066eb1e6d0badd53a2e7fc531e8</gtr:id><gtr:otherNames>Kessler BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1367-5931</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7331011-D368-48F0-8676-9847C51755CD"><gtr:id>B7331011-D368-48F0-8676-9847C51755CD</gtr:id><gtr:title>Signal-peptide-mediated translocation is regulated by a p97-AIRAPL complex.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d75e992e86648738371bf90835bde353"><gtr:id>d75e992e86648738371bf90835bde353</gtr:id><gtr:otherNames>Glinka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BBF57EA0-AA43-48F4-BC09-09F82234D08A"><gtr:id>BBF57EA0-AA43-48F4-BC09-09F82234D08A</gtr:id><gtr:title>PTMs in conversation: activity and function of deubiquitinating enzymes regulated via post-translational modifications.</gtr:title><gtr:parentPublicationTitle>Cell biochemistry and biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db23066eb1e6d0badd53a2e7fc531e8"><gtr:id>6db23066eb1e6d0badd53a2e7fc531e8</gtr:id><gtr:otherNames>Kessler BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1085-9195</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40355BAA-7BA8-4A20-A455-E953517CBE29"><gtr:id>40355BAA-7BA8-4A20-A455-E953517CBE29</gtr:id><gtr:title>Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.</gtr:title><gtr:parentPublicationTitle>Expert reviews in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7fa12e19b3a87c86e7b201ababa1a7c"><gtr:id>a7fa12e19b3a87c86e7b201ababa1a7c</gtr:id><gtr:otherNames>Edelmann MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-3994</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DCB8794C-C676-42FB-A641-038A5EFD48CE"><gtr:id>DCB8794C-C676-42FB-A641-038A5EFD48CE</gtr:id><gtr:title>USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase ?.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/49476d1b28bfaa1e8c55484389b0138d"><gtr:id>49476d1b28bfaa1e8c55484389b0138d</gtr:id><gtr:otherNames>Parsons JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0AE364D1-9CC8-4DF9-B386-DE1A6F7CDE23"><gtr:id>0AE364D1-9CC8-4DF9-B386-DE1A6F7CDE23</gtr:id><gtr:title>Structural basis and specificity of human otubain 1-mediated deubiquitination.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7fa12e19b3a87c86e7b201ababa1a7c"><gtr:id>a7fa12e19b3a87c86e7b201ababa1a7c</gtr:id><gtr:otherNames>Edelmann MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5558FE08-B2DD-4680-A710-74F28EF3266A"><gtr:id>5558FE08-B2DD-4680-A710-74F28EF3266A</gtr:id><gtr:title>Selective Binding of AIRAPL Tandem UIMs to Lys48-Linked Tri-Ubiquitin Chains.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b53ca1b998e826c908ce6d8bc7c6c15"><gtr:id>6b53ca1b998e826c908ce6d8bc7c6c15</gtr:id><gtr:otherNames>Rahighi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12F4FB33-BD68-47F6-8AB1-7D9651CA7826"><gtr:id>12F4FB33-BD68-47F6-8AB1-7D9651CA7826</gtr:id><gtr:title>Ultra-fast tandem mass spectrometry scanning combined with monolithic column liquid chromatography increases throughput in proteomic analysis.</gtr:title><gtr:parentPublicationTitle>Rapid communications in mass spectrometry : RCM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1bcbf4d309dc1eabf131d717f69531ca"><gtr:id>1bcbf4d309dc1eabf131d717f69531ca</gtr:id><gtr:otherNames>Batycka M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0951-4198</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44A487EE-358D-4564-8D27-422B2C2C9B60"><gtr:id>44A487EE-358D-4564-8D27-422B2C2C9B60</gtr:id><gtr:title>Tyrosine dephosphorylation is required for Bak activation in apoptosis.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9dc434bc39e6e38d9509fbfbc1ffeb96"><gtr:id>9dc434bc39e6e38d9509fbfbc1ffeb96</gtr:id><gtr:otherNames>Fox JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F16D1B2-81FB-4405-993C-77C913C249B3"><gtr:id>1F16D1B2-81FB-4405-993C-77C913C249B3</gtr:id><gtr:title>SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/96efb3071f439435d5fdb91ba7913094"><gtr:id>96efb3071f439435d5fdb91ba7913094</gtr:id><gtr:otherNames>Raducu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08F0BA3C-D8E3-4613-8314-FB9FA6B27C10"><gtr:id>08F0BA3C-D8E3-4613-8314-FB9FA6B27C10</gtr:id><gtr:title>Regulation of SUMO2 target proteins by the proteasome in human cells exposed to replication stress.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e213f441fa3a08a69aff0f2821e83c80"><gtr:id>e213f441fa3a08a69aff0f2821e83c80</gtr:id><gtr:otherNames>Bursomanno S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8D854E0-6B59-4EEA-9249-E1BE5714460D"><gtr:id>B8D854E0-6B59-4EEA-9249-E1BE5714460D</gtr:id><gtr:title>Detection of ubiquitin-proteasome enzymatic activities in cells: application of activity-based probes to inhibitor development.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dbf753ff76c52dde307df3f4970ae408"><gtr:id>dbf753ff76c52dde307df3f4970ae408</gtr:id><gtr:otherNames>Kramer HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/962F8F36-F403-4D27-A41F-894215B98869"><gtr:id>962F8F36-F403-4D27-A41F-894215B98869</gtr:id><gtr:title>DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets.</gtr:title><gtr:parentPublicationTitle>Frontiers in genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eba4f749a5371b05cc3d5dc3b67a1acf"><gtr:id>eba4f749a5371b05cc3d5dc3b67a1acf</gtr:id><gtr:otherNames>Pinto-Fernandez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-8021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27BA2383-4587-4C03-9037-7BD3EAF03777"><gtr:id>27BA2383-4587-4C03-9037-7BD3EAF03777</gtr:id><gtr:title>ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6fcc043c12ad570ceb144e48daebd8a"><gtr:id>d6fcc043c12ad570ceb144e48daebd8a</gtr:id><gtr:otherNames>Khoronenkova SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7418DBF1-AAD8-4243-935D-79EF4AD7FD24"><gtr:id>7418DBF1-AAD8-4243-935D-79EF4AD7FD24</gtr:id><gtr:title>Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80b385801defdd9ce2b3d02c9f8ab4dd"><gtr:id>80b385801defdd9ce2b3d02c9f8ab4dd</gtr:id><gtr:otherNames>Altun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E41D391-0344-47FB-B731-992D26E2E414"><gtr:id>2E41D391-0344-47FB-B731-992D26E2E414</gtr:id><gtr:title>Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ab4e18e6860457e66ae750f57975995"><gtr:id>9ab4e18e6860457e66ae750f57975995</gtr:id><gtr:otherNames>Tauriello DV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDFCC2A8-0C34-42AE-9C3C-BF7E7123B61E"><gtr:id>CDFCC2A8-0C34-42AE-9C3C-BF7E7123B61E</gtr:id><gtr:title>Label-free quantitative proteomics reveals regulation of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) and 5'-3'-exoribonuclease 2 (XRN2) during respiratory syncytial virus infection.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f02b9025275703fa69f602064c14a874"><gtr:id>f02b9025275703fa69f602064c14a874</gtr:id><gtr:otherNames>Ternette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D004D5FA-89EB-4C80-9843-A30BE17CEBAD"><gtr:id>D004D5FA-89EB-4C80-9843-A30BE17CEBAD</gtr:id><gtr:title>Proteome changes induced by knock-down of the deubiquitylating enzyme HAUSP/USP7.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db23066eb1e6d0badd53a2e7fc531e8"><gtr:id>6db23066eb1e6d0badd53a2e7fc531e8</gtr:id><gtr:otherNames>Kessler BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0E82805-B5D9-4720-AACC-8487AC7B8B03"><gtr:id>E0E82805-B5D9-4720-AACC-8487AC7B8B03</gtr:id><gtr:title>Comparison of CID versus ETD based MS/MS fragmentation for the analysis of protein ubiquitination.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society for Mass Spectrometry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3ea44665437cedb88251e5995495b37"><gtr:id>b3ea44665437cedb88251e5995495b37</gtr:id><gtr:otherNames>Sobott F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1044-0305</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E61B4CE0-A510-4BE3-B697-70622EBDBC5C"><gtr:id>E61B4CE0-A510-4BE3-B697-70622EBDBC5C</gtr:id><gtr:title>Dia2 controls transcription by mediating assembly of the RSC complex.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18f7a4ae3c77bc0e7e5aacc31e8764d4"><gtr:id>18f7a4ae3c77bc0e7e5aacc31e8764d4</gtr:id><gtr:otherNames>Andress EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB08BF66-313A-4555-BA95-D50D96EE4E92"><gtr:id>EB08BF66-313A-4555-BA95-D50D96EE4E92</gtr:id><gtr:title>Small-molecule-based inhibition of histone demethylation in cells assessed by quantitative mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c89a06316f0208654d8206db82622c96"><gtr:id>c89a06316f0208654d8206db82622c96</gtr:id><gtr:otherNames>Mackeen MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EA5EB14-6693-4118-9F57-6C5BC869C9E8"><gtr:id>4EA5EB14-6693-4118-9F57-6C5BC869C9E8</gtr:id><gtr:title>Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: Emerging patterns and molecular principles.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7fa12e19b3a87c86e7b201ababa1a7c"><gtr:id>a7fa12e19b3a87c86e7b201ababa1a7c</gtr:id><gtr:otherNames>Edelmann MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26452675-8F17-427B-8D3F-46D5A814E73F"><gtr:id>26452675-8F17-427B-8D3F-46D5A814E73F</gtr:id><gtr:title>Putting proteomics on target: activity-based profiling of ubiquitin and ubiquitin-like processing enzymes.</gtr:title><gtr:parentPublicationTitle>Expert review of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db23066eb1e6d0badd53a2e7fc531e8"><gtr:id>6db23066eb1e6d0badd53a2e7fc531e8</gtr:id><gtr:otherNames>Kessler BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1478-9450</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A985498-A78F-4F18-820B-428C7FCB4C54"><gtr:id>8A985498-A78F-4F18-820B-428C7FCB4C54</gtr:id><gtr:title>SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ba0334bcd9992d53572a43b9c6da5d9"><gtr:id>0ba0334bcd9992d53572a43b9c6da5d9</gtr:id><gtr:otherNames>Elliott PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8ADB0FDE-7831-4F64-BBDF-D83555F9AA8C"><gtr:id>8ADB0FDE-7831-4F64-BBDF-D83555F9AA8C</gtr:id><gtr:title>Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/49476d1b28bfaa1e8c55484389b0138d"><gtr:id>49476d1b28bfaa1e8c55484389b0138d</gtr:id><gtr:otherNames>Parsons JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFC804F9-4847-4CB3-8B52-66D60252F775"><gtr:id>DFC804F9-4847-4CB3-8B52-66D60252F775</gtr:id><gtr:title>Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80b385801defdd9ce2b3d02c9f8ab4dd"><gtr:id>80b385801defdd9ce2b3d02c9f8ab4dd</gtr:id><gtr:otherNames>Altun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6111E6A4-0E3C-44B0-8EA5-07F79A1E1B2E"><gtr:id>6111E6A4-0E3C-44B0-8EA5-07F79A1E1B2E</gtr:id><gtr:title>Deubiquitinating enzyme specificity for ubiquitin chain topology profiled by di-ubiquitin activity probes.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18a55eec8a4d0c3958361c9dcc7687a1"><gtr:id>18a55eec8a4d0c3958361c9dcc7687a1</gtr:id><gtr:otherNames>McGouran JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C10E915B-F2B3-4CAB-8F2A-E024E055F37C"><gtr:id>C10E915B-F2B3-4CAB-8F2A-E024E055F37C</gtr:id><gtr:title>Fluorescence-based active site probes for profiling deubiquitinating enzymes.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18a55eec8a4d0c3958361c9dcc7687a1"><gtr:id>18a55eec8a4d0c3958361c9dcc7687a1</gtr:id><gtr:otherNames>McGouran JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/72130D87-2C20-4DB0-823F-9240E772C738"><gtr:id>72130D87-2C20-4DB0-823F-9240E772C738</gtr:id><gtr:title>The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea03f4ddd97e9655301fa7d308345a9a"><gtr:id>ea03f4ddd97e9655301fa7d308345a9a</gtr:id><gtr:otherNames>Vesterlund M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A6E2D405-2552-472C-BF4A-664BF5B14421"><gtr:id>A6E2D405-2552-472C-BF4A-664BF5B14421</gtr:id><gtr:title>Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dbf753ff76c52dde307df3f4970ae408"><gtr:id>dbf753ff76c52dde307df3f4970ae408</gtr:id><gtr:otherNames>Kramer HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F6345EE-4318-444D-8989-EBE9E0F44739"><gtr:id>8F6345EE-4318-444D-8989-EBE9E0F44739</gtr:id><gtr:title>OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/83e105e31e071e9715b88740d423080b"><gtr:id>83e105e31e071e9715b88740d423080b</gtr:id><gtr:otherNames>Iglesias-Gato D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9769485A-31FE-408E-BA13-B205BD1BD782"><gtr:id>9769485A-31FE-408E-BA13-B205BD1BD782</gtr:id><gtr:title>A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a0723009c43c6e66cca3b84676d5016"><gtr:id>3a0723009c43c6e66cca3b84676d5016</gtr:id><gtr:otherNames>Chauhan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501068</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>